DeFloria Inc., a botanical drug development Company recognizes the Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III, as a critical accelerator for cannabinoid ...

Massachusetts correction officers say ‘more needs to be done’ to stop drug smuggling, as DOC reports contraband busts ...

New psychoactive substances, originally developed as potential analgesics but abandoned due to adverse side effects, may still have pharmaceutical value if researchers could nail down the causes of ...

Doctors say the studies may make healthcare providers more likely to prescribe federally approved medical cannabis for chronic lower back pain off-label. And consumers can try experimenting with ...

Marijuana is prescribed to help ease chronic pain and control nausea in cancer patients, but legal red tape has made more ...

President Trump signed an order dropping cannabis from Schedule I to Schedule III. What happens next is crucial. Most needed: ...

POTOMAC, MARYLAND / / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage ...

The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 ...

Though Trump's order marks the biggest shift in federal marijuana policy since 1970, the drug remains illegal in Wisconsin.

The reclassifications of marijuana mark the biggest change to the federal legality of it since 1970. Here's what's happening.

Charlotte’s Web Holdings ( ($TSE:CWEB) ) just unveiled an update. DeFloria Inc., a botanical pharmaceutical developer spun out of Charlotte’s ...

MMJ's position is further fortified by its FDA Orphan Drug Designations for the treatment of Huntington's Disease. These ...